Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Aron Goldhirsch, W. C. Wood, Alan S. Coates et al. · Annals of Oncology · 2011 · 3.9K citations · Full text

Medicine, Oncology, Breast Oncology +16

Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study

Jürgen Geisler, Ben P. Haynes, Gun Anker et al. · Journal of Clinical Oncology · 2002 · 575 citations

Medicine, Oncology, Pharmacology +17

Incidence, Time Course, and Determinants of Menstrual Bleeding After Breast Cancer Treatment: A Prospective Study

Jeanne A. Petrek, Michelle J. Naughton, L. Douglas Case et al. · Journal of Clinical Oncology · 2006 · 433 citations

Medicine, Gynecology, Oncology +12

Anti-Mullerian hormone (AMH): what do we still need to know?

Antonio La Marca, Frank J. Broekmans, Annibale Volpe et al. · Human Reproduction · 2009 · 327 citations · Full text

Medicine, Endocrinology, Gynecology +17

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.

Jürgen Geisler, Nicholas King, Gun Anker et al. · PubMed · 1998 · 316 citations

Medicine, Endocrinology, Pharmacology +17